Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Non-Current Liabilities (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Total Non-Current Liabilities readings, the most recent being $15.1 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 1.66% to $15.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.1 million, a 1.66% decrease, with the full-year FY2025 number at $15.7 million, up 32.47% from a year prior.
  • Total Non-Current Liabilities hit $15.1 million in Q1 2026 for SAB Biotherapeutics, down from $15.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $24.4 million in Q1 2022 to a low of $11.7 million in Q2 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $15.4 million (2025), compared with a mean of $16.1 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 466.41% in 2022 and later tumbled 41.17% in 2023.
  • SAB Biotherapeutics' Total Non-Current Liabilities stood at $19.5 million in 2022, then decreased by 23.86% to $14.9 million in 2023, then fell by 20.39% to $11.8 million in 2024, then surged by 32.47% to $15.7 million in 2025, then dropped by 3.67% to $15.1 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $15.1 million (Q1 2026), $15.7 million (Q4 2025), and $16.0 million (Q3 2025) per Business Quant data.